{
    "clinical_study": {
        "@rank": "31876", 
        "arm_group": [
            {
                "arm_group_label": "Soy", 
                "arm_group_type": "Experimental", 
                "description": "Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules  for 6 weeks"
            }, 
            {
                "arm_group_label": "Soy- Cholecalciferol", 
                "arm_group_type": "Experimental", 
                "description": "Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks"
            }, 
            {
                "arm_group_label": "Cholecalciferol", 
                "arm_group_type": "Experimental", 
                "description": "Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Fasting blood specimens will be taken from the patients with IBS that have inclusion\n      criteria. First, the objectives and method of study will be explained to the patients and\n      informed consent form will be taken from them. They will be divided into 4 groups by an\n      adjusted randomized blocking and the clinical outcomes, quality of life, emotional stress\n      questionnaires will be completed before and after intervention. During 6 weeks, they will\n      receive 2 capsules of soy isoflavones per day, 50000IU vitamin D biweekly in addition to the\n      other placebo form, both of them and placebo of both. At the end, body mass index ( BMI),\n      serum TNF-Alpha, TAC, gene expression of GATA3, ROR gamma, FOXP3 in lymphocytes and gut\n      permeability will be measured. The quantity of polymorphisms of vitamin D and estrogen\n      receptors will be determined."
        }, 
        "brief_title": "Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome", 
        "condition": "Irritable Bowel Disease", 
        "condition_browse": {
            "mesh_term": [
                "Intestinal Diseases", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age 18-75 yrs\n\n          2. patients with Irritable Bowel Syndrome (IBS) according to ROME III criteria\n\n          3. BMI 18-25\n\n          4. a- no intestinal organic diseases b- no intestinal infection c- no history of chronic\n             gastrointestinal and colorectal diseases d- no intestinal major surgery\n\n          5. no regular use of antibiotics, anti-constipation and anti-diarrhea, immune\n             suppressors, metoclopramide, cisapride, diphenoxylate, opium and non-steroidal\n             anti-inflammatory drugs\n\n          6. no pregnancy and lactation\n\n          7. not athlete or bed rest\n\n          8. no history of breast cancer in herself or her family\n\n          9. no severe psychosis\n\n        Exclusion Criteria:\n\n          1. a- use of soy isoflavones or vitamin D one year before the study b- use of soy milk\n             or soy nuts during study\n\n          2. diet changes during study\n\n          3. use of artificial sweetener 2 days before study\n\n          4. no desire to complete the study\n\n          5. adverse effect of supplement\n\n          6. pregnancy during study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026518", 
            "org_study_id": "459"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Soy", 
                    "Soy- Cholecalciferol"
                ], 
                "intervention_name": "Soy isoflavones", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Soy- Cholecalciferol", 
                    "Cholecalciferol"
                ], 
                "intervention_name": "cholecalciferol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Vitamin D"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Cholecalciferol"
                ], 
                "intervention_name": "Placebo of soy isoflavones", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Soy", 
                    "Placebo"
                ], 
                "intervention_name": "placebo of cholecalciferol", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Gastrointestinal Clinics of Tehran University of Medical Sciences"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "jalili.mah@sbmu.ac.ir", 
            "last_name": "Mahsa Jalili, PhD student", 
            "phone": "00989396708282"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in Clinical Outcomes (pain, flatulence, diarrhea, constipation ) at 6 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026518"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shahid Beheshti Medical University", 
            "investigator_full_name": "Mahsa Jalili", 
            "investigator_title": "Mrs", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of baseline in gut permeability as efficacy at 6 weeks", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change of baseline in antioxidant status as efficacy at 6 weeks", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change of baseline in inflammation status as efficacy at 6 weeks", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}